WallStSmart

Boston Scientific Corp (BSX)vsLivaNova PLC (LIVN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 1327% more annual revenue ($21.00B vs $1.47B). BSX leads profitability with a 17.5% profit margin vs 12.8%. BSX appears more attractively valued with a PEG of 0.60. BSX earns a higher WallStSmart Score of 72/100 (B).

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 1.78

LIVN

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 6.0Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.35
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXOvervalued (-10.0%)

Margin of Safety

-10.0%

Fair Value

$39.07

Current Price

$42.98

$3.91 premium

UndervaluedFair: $39.07Overvalued
LIVNUndervalued (+7.7%)

Margin of Safety

+7.7%

Fair Value

$71.98

Current Price

$78.18

$6.20 discount

UndervaluedFair: $71.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX6 strengths · Avg: 8.2/10
Market CapQuality
$62.29B9/10

Large-cap with strong market position

PEG RatioValuation
0.608/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

LIVN3 strengths · Avg: 9.0/10
EPS GrowthGrowth
287.8%10/10

Earnings expanding 287.8% YoY

Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.938/10

Growing faster than its price suggests

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

LIVN1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
0.352/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bull Case : LIVN

The strongest argument for LIVN centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 10.8% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : LIVN

The primary concerns for LIVN are Altman Z-Score.

Key Dynamics to Monitor

BSX profiles as a mature stock while LIVN is a value play — different risk/reward profiles.

LIVN carries more volatility with a beta of 0.87 — expect wider price swings.

LIVN is growing revenue faster at 10.8% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 68/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

LivaNova PLC

HEALTHCARE · MEDICAL DEVICES · USA

LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.

Visit Website →

Want to dig deeper into these stocks?